ProCE Banner Activity

SIRIUS: Daratumumab Active, Safe in Double Refractory Multiple Myeloma

Slideset Download
Conference Coverage
In this population of patients who had received a median of 5 prior therapies over 5 years and were refractory to most available agents, daratumumab was associated with an ORR of 29%; no patients discontinued due to adverse events.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation